1
|
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol 2023; 34:1141-1151. [PMID: 38072514 DOI: 10.1016/j.annonc.2023.09.3104] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 08/24/2023] [Accepted: 09/13/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, and has antitumor activity in ESR1-mutated xenografts. PATIENTS AND METHODS In this open-label, randomized, phase II, multicenter, ELAINE 1 study (NCT03781063), we randomized women with ESR1-mutated, ER+/human epidermal growth factor receptor 2 negative (HER2-) mBC that had progressed on an aromatase inhibitor (AI) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) to oral lasofoxifene 5 mg daily or IM fulvestrant 500 mg (days 1, 15, and 29, and then every 4 weeks) until disease progression/toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were safety/tolerability. RESULTS A total of 103 patients received lasofoxifene (n = 52) or fulvestrant (n = 51). The most current efficacy analysis showed that lasofoxifene did not significantly prolong median PFS compared with fulvestrant: 24.2 weeks (∼5.6 months) versus 16.2 weeks (∼3.7 months; P = 0.138); hazard ratio 0.699 (95% confidence interval 0.434-1.125). However, PFS and other clinical endpoints numerically favored lasofoxifene: clinical benefit rate (36.5% versus 21.6%; P = 0.117), objective response rate [13.2% (including a complete response in one lasofoxifene-treated patient) versus 2.9%; P = 0.124], and 6-month (53.4% versus 37.9%) and 12-month (30.7% versus 14.1%) PFS rates. Most common treatment-emergent adverse events with lasofoxifene were nausea, fatigue, arthralgia, and hot flushes. One death occurred in the fulvestrant arm. Circulating tumor DNA ESR1 mutant allele fraction (MAF) decreased from baseline to week 8 in 82.9% of evaluable lasofoxifene-treated versus 61.5% of fulvestrant-treated patients. CONCLUSIONS Lasofoxifene demonstrated encouraging antitumor activity versus fulvestrant and was well tolerated in patients with ESR1-mutated, endocrine-resistant mBC following progression on AI plus CDK4/6i. Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent than fulvestrant. Lasofoxifene may be a promising targeted treatment for patients with ESR1-mutated mBC and warrants further investigation.
Collapse
Affiliation(s)
- M P Goetz
- Department of Oncology, Mayo Clinic, Rochester.
| | - N A Bagegni
- Division of Oncology, Washington University School of Medicine, St. Louis, USA
| | - G Batist
- Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - A Brufsky
- University of Pittsburgh Medical Center-Magee Women's Hospital, Pittsburgh
| | - M A Cristofanilli
- Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York
| | - S Damodaran
- The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston
| | | | - G F Fleming
- The University of Chicago Medical Center, Chicago
| | - W J Gradishar
- Division of Hematology/Oncology, Northwestern University, Chicago
| | - S L Graff
- Lifespan Cancer Institute/Legorreta Cancer Center at Brown University, Providence
| | | | - E Hamilton
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville
| | - S Lavasani
- Division of Hematology and Medical Oncology, UC Irvine, Orange
| | | | - T O'Connor
- Roswell Park Comprehensive Cancer Center, Department of Medicine, Buffalo
| | - T J Pluard
- Saint Luke's Cancer Institute, Kansas City
| | - H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco
| | - S L Sammons
- Dana Farber Cancer Institute, Harvard Medical School, Boston
| | | | - D G Stover
- Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus
| | - G A Vidal
- Breast Oncology Division, West Cancer Center, Memphis
| | - G Wang
- Medical Oncology, Miami Cancer Institute at Baptist Health, Miami, USA
| | - E Warner
- Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - R Yerushalmi
- Rabin Medical Center, Beilinson Hospital, Petah Tikva, Tel-Aviv University, Tel-Aviv, Israel
| | | | | | - E N Gal-Yam
- Breast Oncology Institute, Sheba Medical Center, Ramat Gan, Israel
| |
Collapse
|
2
|
O'Shaughnessy J, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Cheung E, Han HS, Daniel BR, Vojnovic Z, Vasev N, Ling M, Richards DA, Wilks ST, Milenkovic D, Sorrentino JA, Roberts PJ, Bomar M, Yang Z, Antal JM, Malik RK, Morris SR, Tan A. Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cytotoxic chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPCs) results in acute toxicities consisting of multi-lineage myelosuppression, and late onset toxicities consisting of progressive bone marrow suppression with increased incidence of therapy-related myeloid neoplasms. T is an IV CDK4/6 inhibitor in development to preserve HSPC and immune system function during cytotoxic chemotherapy (myelopreservation). Proof of concept for myelopreservation with T was observed in a randomized, placebo-controlled Phase 2 trial in small-cell lung cancer patients receiving 1st-line chemotherapy. This trial in mTNBC patients (NCT02978716) was designed to explore the utility of T in combination with GC.
Methods: This Phase 2, randomized, open-label study enrolled patients in the US and EU with mTNBC who had received 0-2 prior systemic cytotoxic therapies in the locally recurrent or metastatic setting and had no symptomatic brain metastases. Patients were randomized (1:1:1) to GC alone (Group 1) or T plus GC (Group 2) using a standard schedule (D1, 8 every 21 days) or to an alternative schedule (T on D1, 2, 8 and 9 with GC on D2 and 9 every 21 days; Group 3). On those days when both T and GC were scheduled, T was administered iv prior to GC infusion. Prophylactic growth factors were not administered in cycle 1; otherwise supportive care was allowed as needed. Primary objectives were safety and tolerability; tumor response was evaluated using RECIST v1.1 and PFS and OS were assessed. Myelopreservation endpoints reflecting the potential effects of T on multiple cellular lineages include occurrence of Grade 4 neutropenia (primary), RBC and platelet transfusions (primary), and lymphocyte counts with immune profiling (secondary and exploratory). A signature of CDK4/6 independence developed from preclinical data will be used to evaluate archival tumor tissue samples and data analysis is ongoing.
Results: 95 patients were dosed; median age 57 years (range 32,86), ECOG PS 0 (53%) or 1 (47%), 25% had liver metastases at baseline, and approximately 50% had received no systemic therapy in the recurrent/metastatic setting. Fifty-five patients remain on treatment. Disease progression was the most common reason for drug discontinuation (22/40; 55%). Overall the most common (≥ 25%) TEAEs were anemia (47%), nausea (35%), fatigue (34%), neutropenia (32%), platelet count decreased (25%), and vomiting (25%). The most frequent (≥ 15%) Grade 3 or 4 TEAEs were hematologic toxicities, i.e. neutropenia (28%), anemia (21%), neutrophil count decreased (21%) and thrombocytopenia (16%). These were also the most frequent drug-related TEAEs observed. Tumor efficacy data are being evaluated.
Conclusions: This trial, assessing the myelopreservation effects of T when combined with GC in patients with mTNBC, has completed enrollment. Myelopreservation data, immune profiling, as well as ORR and preliminary PFS results will be presented by study arm at the meeting.
Citation Format: O'Shaughnessy J, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Cheung E, Han HS, Daniel BR, Vojnovic Z, Vasev N, Ling M, Richards DA, Wilks ST, Milenkovic D, Sorrentino JA, Roberts PJ, Bomar M, Yang Z, Antal JM, Malik RK, Morris SR, Tan A. Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-01.
Collapse
Affiliation(s)
- J O'Shaughnessy
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - GS Wright
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - AR Thummala
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - MA Danso
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - L Popovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - TJ Pluard
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - E Cheung
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - HS Han
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - BR Daniel
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - Z Vojnovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - N Vasev
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - M Ling
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - DA Richards
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - ST Wilks
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - D Milenkovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - JA Sorrentino
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - PJ Roberts
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - M Bomar
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - Z Yang
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - JM Antal
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - RK Malik
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - SR Morris
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - A Tan
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| |
Collapse
|
3
|
Geske SJ, Pluard TJ, Amazu C, Holden R. Abstract P1-11-20: Patient reported supportive care needs in a dedicated advanced breast cancer center. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As of January 1st, 2017 nearly 154,794 women in the US will be living with metastatic breast cancer (MBC) and rates are expected to increase. Additionally, 58.3% of individuals with MBC, and their caregivers, believe that people with MBC have unique informational, emotional and physical needs that are unmet. However, there are still few research studies examining these needs.
Methods: In October of 2016, the Koontz Center for Advanced Breast Cancer was established in Kansas City, MO. Supportive services assume a large role in this center to assist in caring for the whole person and improving quality of life. During the initial consult, the patient meets with the medical oncologist, psychologist, social worker, nutritionist, exercise physiologist and chaplain. All patients complete forms assessing multiple domains that may influence the patient's treatment and outcomes. We use the PROMIS (Patient-Reported Outcome Measurement Information System) measures to assess sleep, physical function, fatigue and pain interference, the Daily Spiritual Experience Scale (DSES) to assess spiritual concerns, the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult to assess mental health concerns and Koontz Center forms to assess social work and nutritional concerns. The following data is from assessments collected through May of 2018.
Results: Eighty-two individuals were included in the analysis. The mean age was 60.1 (SD=10.6) and 98% (n=80) were female. A majority were white, non-Hispanic (88%; n=71). Sleep related impairment was mild for 27 (33.8%) individuals, moderate for 22 (27.5%) and severe for 3 (3.8%). For physical function, 12 (14.8%) individuals had mild, 32 (39.5%) moderate and 19 (23.5%) severe impairment. Twelve (15%) individuals had mild, 25 (31.3%) moderate and 6 (7.5%) severe symptoms of fatigue. For pain interference, 14 (17.3%) individuals had mild, 24 (29.6%) moderate and 9 (11.1%) severe symptoms. The average DSES score was 12.6 (SD=6.8) out of 36 with lower scores indicating stronger spiritual satisfaction. The top three mental health concerns were anxiety (n=47; 58.8%), depression (n=40; 50%) and somatic symptoms (n=38; 47.5%). Seventeen percent (n=14) reported concern over weight and 30% (n=24) reported losing weight over the past two weeks. The top three areas individuals reported needing assistance in were finding financial resources (n=16; 20.5%), help at home (n=11; 14.1%) and insurance questions (n=10; 12.8%). The top four areas individuals reported needing support in were information on support groups (n=20; 25.6%), managing stress (n=20; 25.6%), coping with cancer diagnosis (n=14; 17.9%) and communicating with children about cancer (n=14; 17.9%). Also, 38% (n=28) endorsed wanting information about an advanced directive. Changes across age and symptom complexes were also noted and will be presented.
Conclusion: The data indicate that there are a wide variety of physical, spiritual, nutritional, social and psychological concerns for those coping with a MBC diagnosis. Future treatment of those with MBC should integrate supportive services to address these symptoms.
Citation Format: Geske SJ, Pluard TJ, Amazu C, Holden R. Patient reported supportive care needs in a dedicated advanced breast cancer center [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-20.
Collapse
Affiliation(s)
- SJ Geske
- Saint Luke's Cancer Institute, Kansas City, MO
| | - TJ Pluard
- Saint Luke's Cancer Institute, Kansas City, MO
| | - C Amazu
- Saint Luke's Cancer Institute, Kansas City, MO
| | - R Holden
- Saint Luke's Cancer Institute, Kansas City, MO
| |
Collapse
|
4
|
Rich TA, Raymond VM, Ahn ER, Banks KC, Brufsky A, Lee C, Lippman M, Pluard TJ, Schwab RB, Lanman RB. Abstract P4-01-05: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 equivocal breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Determination of ERBB2 (HER2) expression or amplification informs eligibility of HER2-targeted therapies. ASCO and NCCN guidelines recommend evaluation of HER2 status on primary invasive breast cancers and on a metastatic site if stage IV, where possible, as treatment is based on the status of the metastasis. Reassessment of HER2 status should also be considered in patients with disease recurrence as initially HER2-negative tumors may acquire HER2 amplification at progression. HER2 status can be complicated by equivocal results from in situ hybridization (ISH) and/or immunohistochemistry (IHC). Clarification requires reflex testing on the same tissue specimen or repeat testing on a new specimen, however some patients' tissue status remains equivocal. Furthermore, metastases to bone, lung, or brain may be difficult to re-biopsy or of low DNA quality. Rapid and non-invasive blood-based cell-free DNA (cfDNA) NGS may facilitate identification of HER2 targetable disease in advanced breast cancer.
Methods:
We assessed the frequency of ERBB2 amplification detectable by a blood-based cell-free DNA (cfDNA) assay among patients with metastatic breast cancer with equivocal HER2 results in tissue. cfDNA samples were ordered as part of routine clinical care using an assay validated for the detection of copy number amplification in ERBB2 (tests run between 03/2014-04/2017 by Guardant Health, Redwood City, CA). Submitted pathology reports were reviewed for HER2 status which was categorized as positive, negative, or equivocal based on the interpretation issued by the reading pathologist at the time the test was ordered. Patients were included if they had an equivocal result on IHC and/or ISH unless both assays were performed on the same specimen and one provided a definitive negative or positive HER2 result. Additionally, 4 patients with equivocal IHC or ISH results were excluded as biopsy of another tumor site revealed a positive HER2 result around the same time as the equivocal test. For the 349 patients with multiple cfDNA samples, the earliest pathology report was referenced.
Results:
Tissue HER2 status was available for 1,853 unique patients (98.8% female, median age at testing was 58y, range 26-91y). 141 patients (7.6%) had equivocal HER2 results in tissue; 99 by IHC alone, 14 by ISH alone, and 28 were equivocal by both assays. Among these, 126 patients (89.4%) had at least one sample with ctDNA detected. 12/126 (9.5%) had amplification of ERBB2 detected in at least one cfDNA sample. Samples were drawn a median of 267 days after tissue collection (range 4 days – 11.5 years). Frequency of ERBB2 amplification was similar regardless of time between tissue and blood collection but was higher among patients with ISH results alone (4/14, 36.4%) compared to those with IHC alone (6/89, 6.7%) or both assays (6/26, 7.6%; p=0.006).
Conclusion:
cfDNA testing identifies a significant number of patients with HER2-targetable advanced breast cancer whose tissue was HER2 equivocal. cfDNA testing may supplement tissue-based methods to help clarify HER2 status in metastatic disease as well as identify patients who may acquire HER2 amplification subsequent to their initial biopsy.
Citation Format: Rich TA, Raymond VM, Ahn ER, Banks KC, Brufsky A, Lee C, Lippman M, Pluard TJ, Schwab RB, Lanman RB. Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 equivocal breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-05.
Collapse
Affiliation(s)
- TA Rich
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - VM Raymond
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - ER Ahn
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - KC Banks
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - A Brufsky
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - C Lee
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - M Lippman
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - TJ Pluard
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - RB Schwab
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| | - RB Lanman
- Guardant Health, Redwood City, CA; Cancer Treatment Centers of America, Chicago; University of Pittsburgh Medical Center - Magee-Women's Hospital, Pittsburgh; University of Miami Miller School of Medicine, Miami; St. Luke's Cancer Institute, Kansas City; University of California San Diego Moores Cancer Center, La Jolla
| |
Collapse
|
5
|
Cortes J, Martin M, Pernas S, Gomez Pardo P, Lopez-Tarruella S, Gil-Martin M, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Wach A, Barker D, Romagnoli B, Kaufman PA. Abstract PD1-02: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Cortes J, Martin M, Pernas S, Gomez Pardo P, Lopez-Tarruella S, Gil-Martin M, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Wach A, Barker D, Romagnoli B, Kaufman PA. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-02.
Collapse
Affiliation(s)
- J Cortes
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Martin
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Pernas
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - P Gomez Pardo
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Lopez-Tarruella
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Gil-Martin
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - L Manso
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - E Ciruelos
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - JA Perez-Fidalgo
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - C Hernando
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - FO Ademuyiwa
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - K Weilbaecher
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - I Mayer
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - TJ Pluard
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Martinez Garcia
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - L Vahdat
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - A Wach
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - D Barker
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - B Romagnoli
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - PA Kaufman
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
6
|
Han HS, Wilks S, Paplomata E, Modiano MR, Becerra C, Braiteh FS, Spira AI, Pluard TJ, Richards DA, Conzen SD, Baker G, Fishman RS, Marcantonio A, O'Shaughnessy J, Nanda R. Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-12-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: GR is variably expressed in TNBC and high expression is associated with poor prognosis in estrogen receptor-negative (ER-) early stage breast cancer. Treatment with mifepristone (MIFE) potentiates the effectiveness of chemotherapy in GR+ TNBC xenografts. Enrollment is complete in this study of patients with GR+ TNBC treated at the recommended Phase 2 dose (RP2D) of MIFE in combination with eribulin. Objectives: To determine the safety, tolerability, pharmacokinetics (PK) and clinical activity of the MIFE plus eribulin combination in pts with GR+ TNBC at the RP2D. Methods: Eligibility: In Part 1 (dose finding), pts with solid tumors; in Part 2 (expansion phase), pts with TNBC (GR result required at time of screening in Part 1, but could be pending at time of screening in Part 2). Up to 5 prior chemotherapy regimens for advanced disease; ECOG PS 0-1; adequate end-organ function. Design: 3 + 3 dose escalation scheme. After a 7-day lead-in of oral daily MIFE alone, MIFE was continued daily and eribulin was given on days 1 and 8 of a 21-day cycle. GR+ was defined as >10% of tumor cells with any intensity of GR staining. Results: 16 pts with metastatic breast cancer were treated in Part 1, and 21 pts with TNBC were treated in Part 2. Median age was 54 (range 30-81). MTD/RP2D was MIFE 300 mg/day + eribulin 1.1 mg/m2. Safety: DLT in Part 1 was neutropenia. Neutropenia occurred in 23/36 total patients (2 Grade [G] 1, 10 G3, 11 G4); 2 instances included neutropenic fever. Recovery of WBC was brisk with growth factor support. Neuropathy was observed in 8 pts (5 G1, 1 G2, 2 G3). Other most common AEs (fatigue, hypokalemia, nausea, alopecia) were mainly G1 or G2; among these, G3/G4 events were limited to fatigue (4 G3), hypokalemia (3 G3 and 1 G4) and nausea (1 G3). There were 2 instances of G1 vaginal bleeding. There was no impact of MIFE on eribulin PK. Efficacy: There were 23 evaluable pts with TNBC across Parts 1 and 2 treated at the RP2D: 21 GR+, 2 GR status unknown; median of 3 prior chemotherapy regimens; 1 patient had received prior eribulin. Responses were: 3 PR, 8 SD, 11 PD and one too early to assess. Median PFS was 9 weeks. Conclusions: MIFE plus eribulin was well tolerated and appears to be an active treatment regimen. Five TNBC patients had a PFS longer than the upper 95% CI for PFS (i.e., >15 wks) reported by Aogi et al. for TNBC treated with eribulin (Annals of Oncology 2012?23:144148). Clinical trial information: NCT02014337.
Citation Format: Han HS, Wilks S, Paplomata E, Modiano MR, Becerra C, Braiteh FS, Spira AI, Pluard TJ, Richards DA, Conzen SD, Baker G, Fishman RS, Marcantonio A, O'Shaughnessy J, Nanda R. Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-15.
Collapse
Affiliation(s)
- HS Han
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - S Wilks
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - E Paplomata
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - MR Modiano
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - C Becerra
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - FS Braiteh
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - AI Spira
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - TJ Pluard
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - DA Richards
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - SD Conzen
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - G Baker
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - RS Fishman
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - A Marcantonio
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - J O'Shaughnessy
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| | - R Nanda
- Texas Oncology San Antonio; ACRC/Arizona Clinical Research Center and Arizona Oncology; Virginia Cancer Specialists Research Institute; Texas Oncology - Baylor Charles A Sammons Cancer Center; Moffitt Cancer Center; The US Oncology Network/Mckesson Specialty Health; Emory University Winship Cancer Institute Midtown; Saint Luke's Cancer Institute; Tyler Cancer Center, US Oncology Research; Baylor University Medical Center Texas Oncology US Oncology, Dallas, TX; Corcept Therapeutics, Inc; University of Chicago Medical Center; Beth Israel Deaconess Medical Center
| |
Collapse
|
7
|
Moley JF, Adkins D, Bible KC, Traynor AM, Molina JR, Colon-Otero G, Pluard TJ, Shah MH, Suresh R, Erlichman C, Ivy SP, Suman V, Geyer SM, Fracasso PM, Cohen MS, Tang H, Fialkowski E, Traugott A, Smallridge RC. 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Samuel TA, Sessa C, Britten C, Milligan KS, Mita MM, Banerji U, Pluard TJ, Stiegler P, Quadt C, Shapiro G. AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2528] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla KN, Mita MM, Pluard TJ, Stiegler P, Quadt C, Shapiro GI. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3532] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3532^ Background: AUY922, a novel isoxazole-based HSP90 inhibitor, causes the degradation of multiple cellular tumor promoting targets. Preclinical evidence suggests broad anti-tumor activity of AUY922, warranting clinical development. Methods: Single agent AUY922 was administered as IV infusion over 1h once a week to patients (pts) with advanced solid malignancies, utilizing a Bayesian design for dose-escalation. The primary endpoint was determination of the maximum tolerated dose of AUY922; secondary endpoints included safety, tolerability, preliminary activity, PK and PD. Results: Between Jul 2007 and Dec 2008, 44 pts with were treated at dose levels of 2 mg/m2 (3pts), 4 mg/m2 (4pts), 8 mg/m2 (5pts), 16 mg/m2 (7pts), 22 mg/m2 (11pts), 28 mg/m2 (7pts) and 40 mg/m2 (7pts). Median age was 56 years; 95% of pts had a WHO performance status 0 or 1. The most frequently reported adverse events were nausea in 19 patients (50.0 %), diarrhea in 18 patients (47.4 %), fatigue in 15 patients (39.5 %), and vomiting in 9 patients (23.7 %). Grade 1 and 2 diarrhea, fatigue, nausea and vomiting were suspected to be related to AUY922 at doses ≥ 8 mg/m2. Grade 3 events, including atrial flutter, 1pt, at 22 mg/m2, anorexia, fatigue and diarrhea, 2 pts, at 40 mg/m2, were reported as dose limiting toxicities. Expansion of the 40 mg/m2 cohort was initiated in Dec 2008. The median terminal half life of AUY922 at doses up to 28 mg/m2 was 56 h (24 to 108 h). Pharmacodynamic analyses show dose proportional induction of HSP70 in peripheral blood mononuclear cells by AUY922. Six pts achieved disease stabilization for at least 16 and up to 64 weeks. Conclusions: Single-agent AUY922, administered as a weekly infusion, is well tolerated at doses up to 40 mg/m2. Prolonged disease stabilization was seen in a subset of patients receiving AUY922 across dose levels. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .
Collapse
Affiliation(s)
- C. Sessa
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - S. K. Sharma
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - C. D. Britten
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - N. J. Vogelzang
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - K. N. Bhalla
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - M. M. Mita
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - T. J. Pluard
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - P. Stiegler
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - C. Quadt
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| | - G. I. Shapiro
- IOSI, Bellinzona, Switzerland; Nevada Cancer Institute, Las Vegas, NV; UCLA Medical Center, Los Angeles, CA; Nevada Cancer Institute, Las Vegas, NV; Medical College of Georgia, Augusta, GA; University of Texas Health Science Center, San Antonio, TX; Washington University School of Medicine, St Louis, MO; Novartis Pharmaceuticals, Florham Park, NJ; Novartis Pharmaceuticals, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|